608482 Provided are crystalline forms of (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl) ethanol. A preferred crystalline form is (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl) ethanol monohydrate. A crystalline form can be characterised by the X-ray powder diffraction pattern (Cu radiation, λ = 1.54059 Å) comprising a peak at 14.65 (20+/-0.1°) and comprising further peaks at 3.54 (20+/-0.1°), 12.51 (20+/-0.1°) and 19.16 (20+/-0.1°). The crystalline forms can be used in the treatment of cancer. Further provided is a pharmaceutical composition comprising the crystalline forms.
